BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 4,870,000 shares, a decrease of 7.1% from the October 15th total of 5,240,000 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is presently 4.0 days.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a report on Monday, September 16th. HC Wainwright downgraded BioAtla from a “buy” rating to a “neutral” rating in a report on Wednesday, November 13th.

Institutional Trading of BioAtla

Institutional investors and hedge funds have recently modified their holdings of the business. Vontobel Holding Ltd. bought a new position in shares of BioAtla during the third quarter valued at approximately $28,000. Ground Swell Capital LLC purchased a new stake in shares of BioAtla during the second quarter valued at $33,000. Valmark Advisers Inc. purchased a new stake in BioAtla during the second quarter valued at about $34,000. Rinkey Investments acquired a new position in BioAtla in the 2nd quarter worth approximately $35,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of BioAtla in the third quarter worth $44,000. 77.23% of the stock is owned by institutional investors and hedge funds.

BioAtla Stock Down 3.2 %

Shares of NASDAQ BCAB opened at $1.51 on Tuesday. BioAtla has a 1-year low of $1.14 and a 1-year high of $4.02. The business has a 50-day moving average of $1.91 and a 200-day moving average of $1.85.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million during the quarter. During the same quarter in the previous year, the company earned ($0.70) earnings per share. Analysts anticipate that BioAtla will post -1.49 EPS for the current fiscal year.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.